Welcome to our dedicated page for Synlogic news (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic stock.
Synlogic, Inc. news has centered on financial results and corporate updates for a biopharmaceutical company that developed genetically engineered probiotic drug candidates. Synlogic designed, developed, and manufactured drug candidates using precision genetic engineering applied to well-characterized probiotics, including GI-restricted orally administered biopharmaceuticals.
Recurring updates have covered the discontinuation of Synpheny-3, the pivotal study of labafenogene marselecobac (SYNB1934) in phenylketonuria, strategic-review activity, a limited-duration stockholder rights plan, Roche collaboration revenue, restructuring charges, and published data for SYNB1353 in classical homocystinuria.
Synlogic (OTC:SYBX) and Caldera Therapeutics entered a definitive all‑stock merger agreement under which both will become subsidiaries of a newly formed holding company that will operate as Caldera Therapeutics and seek listing on the Nasdaq Capital Market under the ticker “CALD.”
Concurrently, Caldera secured commitments for an upsized $278 million private placement from healthcare institutional investors and mutual funds. Combined with existing cash, these funds are expected to support development and operations into 2029, including Phase 2 trials of lead asset CLD‑423 in ulcerative colitis and Crohn’s disease.
Post‑merger, pre‑transaction Synlogic stockholders are expected to own about 2.3% of the combined company, Caldera stockholders about 62.8%, and private placement investors about 34.9%, subject to adjustment based on Synlogic’s net cash. The deal, approved by both boards, is expected to close by early 2027, pending shareholder approvals, SEC registration effectiveness, and other customary conditions.
Synlogic (NASDAQ: SYBX) has reported its Q3 2024 financial results. The company ended the quarter with $19.4 million in cash and cash equivalents. The company reported no revenue, compared to $0.4 million in Q3 2023. There was a $0.7 million benefit in R&D expenses, compared to $9.6 million expenses in Q3 2023, due to clinical trial closeouts and Synpheny-3 discontinuation. G&A expenses decreased to $1.2 million from $3.4 million year-over-year. The company reported a net loss of $0.1 million ($0.01 per share), improved from a $12.1 million loss ($2.57 per share) in Q3 2023. The company has retained Lucid Capital Markets to explore strategic alternatives.
Synlogic, Inc. (Nasdaq: SYBX) reported its Q2 2024 financial results and provided a corporate update. Key points include:
1. Cash and cash equivalents of $20.0 million as of June 30, 2024.
2. No revenue for Q2 2024, compared to $35,000 in Q2 2023.
3. R&D expenses decreased to $2.2 million from $11.8 million year-over-year.
4. G&A expenses reduced to $1.2 million from $3.9 million year-over-year.
5. Reported a net income of $2.0 million ($0.16 per share) due to restructuring gains, compared to a net loss of $15.0 million in Q2 2023.
6. The company is exploring strategic options, including potential acquisition or merger, to maximize shareholder value.
Synlogic (Nasdaq: SYBX) reported its first-quarter 2024 financial results on May 14, 2024. The company's revenue for Q1 2024 was $0.01 million, a significant decrease from $0.2 million in Q1 2023. Research and development expenses were reduced to $7.7 million from $12.5 million in the same period last year, while general and administrative expenses dropped to $2.9 million from $4.0 million. Notably, the company incurred $28.2 million in restructuring charges due to discontinuing its Synpheny-3 study. Synlogic reported a consolidated net loss of $31.6 million, or $2.60 per share, compared to a net loss of $15.6 million, or $3.39 per share, in Q1 2023. The company has retained Lucid Capital Markets to explore strategic alternatives.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.